Abiraterone Acetateabiraterone acetate is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
:- metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.
oral; 1000mg once daily with prednisone. Take empty stomach
Paediatric: Safety not yet established Pregnancy: Category X; Contraindicated Lactation: Not to be given Elderly: Safety similar to adult
joint swelling or discomfort, hypokalemia, edema, muscle discomfort, hot flush, diarrhea, urinary tract infection, cough, hypertension, arrhythmia, urinary frequency, nocturia, dyspepsia, and upper respiratory tract infection.
Avoid co-administration with CYP2D6 substrates that have a narrow therapeutic index.
|Brand Name||Manufactured by|
|ZYBUCA||BRUCK PHARMA PVT.LTD|